Compositions in the form of an injectable aqueous solution including at least human insulin A21G and a glucagon suppressor with prandial action
A composition in the form of an injectable aqueous solution, with pH from 3.5 to 4.4, including at least human insulin A21G and at least one glucagon suppressor with prandial action. In an embodiment, the glucagon suppressor with prandial action is selected from an amylin analog or an amylin receptor agonist or a GLP-1 analog or a GLP-1 receptor agonist (GLP-1 RA). In an embodiment, the glucagon suppressor with prandial action is an amylin analog or an amylin receptor agonist. In an embodiment, the glucagon suppressor peptide with prandial action is pramlintide. Also, a method for obtaining human insulin A21G, includes at least one step of reacting human insulin A21G, B31R, B32R (insulin glargine) with rat carboxypeptidase B at an insulin/carboxypeptidase ratio from 500 to 2000, at a pH from 7.5 to 8.5 and a temperature from 20 to 30° C. for 10 to 20 hours.
1. A composition in the form of an injectable aqueous solution, the pH of which is from 3.5 to 4.4, including at least human insulin A21G referred to as regular in a range from 100 to 300 U/ml and pramlintide at a concentration of between 0.4 to 3.0 mg/ml.
2. A composition according to claim 1 , wherein the concentration of human insulin A21G is in a range from 100 to 200 U/ml.
3. The composition according to claim 1 , wherein the concentration of human insulin A21G is 100 U/ml.
4. The composition according to claim 1 , wherein the concentration of human insulin A21G is 200 U/ml.
5. The composition according to claim 1 , wherein the concentration of pramlintide ranges from 0.5 to 1.5 mg/ml.
6. The composition according to claim 1 , wherein the concentration of pramlintide ranges from 0.6 to 1 mg/ml per 100 U/ml of human insulin A21G.
7. The composition according to claim 1 , wherein the pH of the solution is from 3.8 to 4.2.
8. The composition according to claim 1 , wherein the pH of the solution is 4.0.
9. The composition according to claim 1 , wherein the composition further includes a zinc salt.
10. The composition according to claim 1 , wherein the composition further includes m-cresol.
11. The composition according to claim 1 , wherein the composition further includes a surfactant selected from the group consisting of Poloxamer 188, Polysorbate 20, and Polysorbate 80.
12. The composition according to claim 1 , wherein the composition further includes a poloxamer 188 excipient.
13. The composition according to claim 1 , wherein the composition further includes methionine.
14. The composition according to claim 1 , wherein the composition is used in a diabetes treatment method, wherein the composition is administered in a bolus before meals.
15. The composition according to claim 1 , wherein the composition is used in a diabetes treatment method, wherein the composition is administered to improve control of postprandial glycemia.
16. The composition according to claim 1 , wherein the composition is used in a diabetes treatment method, wherein the composition is administered to improve control of postprandial glycemia and to decrease the adverse effects of pramlintide.
17. The composition according to claim 1 , wherein the composition is used in a diabetes treatment method, wherein the composition enables a decrease in food consumption induced by insulin.
18. A solid composition comprising at least human insulin A21G referred to as regular and pramlintide in a ratio from 33 to 167 U insulin /mg of pramlintide.
19. A method for treating a diabetic patient in need of an insulin formulation, comprising administering by injection to said patient a composition comprising at least human insulin A21G referred to as regular in a concentration range from 100 to 300 U/ml and pramlintide at a concentration range from 0.4 to 3 mg/ml, wherein the pH of the composition is in a range from 3.5 to 4.4.